Clinical Trial Update: Oral Auranofin for Reduction of Latent Viral Reservoir in Patients With HIV Infection [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 clinical trial evaluating oral auranofin for reducing latent HIV reservoir has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Auranofin (auranofin)

Snippet

Sponsor: Vaccine and Gene Therapy Institute, Florida | Conditions: HIV | Phase 1, Phase 2 | Status: WITHDRAWN